Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 75,71 € (+3,25 %). Medianen er 75,83 € (+3,41 %).

Køb	13
Behold	8
Sælg	0

Nyheder Til nyhedsfeedet

Crinetics Pharmaceuticals reaches record high at $84.8

Crinetics Pharmaceuticals’ stock rose to a record high of $84.8, lifting its market capitalization to about $9 billion. The company reported strong revenue growth with net product revenues of $24.0 million in Q2 2026 and total revenue of $25.1 million. The planned roughly $10 billion acquisition by Vertex has advanced following regulatory approvals, but analysts reacted with downgrades. Data indicate the stock may be temporarily above its fair value and overbought. » Mere på de.investing.com
Crinetics merger with Vertex clears major antitrust hurdles

The planned takeover of Crinetics by Vertex has passed important antitrust waiting periods and received approvals in Austria, Germany and Australia. The transaction envisages a cash price of $85 per share (around $10 billion) and remains subject, among other things, to approval by Crinetics shareholders on August 28, 2026; closing is expected in early September or in the third quarter of 2026. Crinetics shares are trading near their 52-week high, and the company reported strong revenue growth for Palsonify in the second quarter of 2026. » Mere på de.investing.com
Crinetics Pharmaceuticals hits record high at $84.35 after Vertex acquisition announcement

Crinetics Pharmaceuticals shares rose to a record high of $84.35 and are trading near their 52-week high; market capitalization is about $8.94 billion. Vertex announced a takeover of Crinetics for $85 per share (about $10 billion), with completion expected in Q3 2026. Crinetics reported strong revenue growth driven by Palsonify (Q2 revenue $24.0 million; total revenue $25.1 million) and has posted double-digit gains year-to-date, while some analysts have cut ratings from buy to neutral/hold and InvestingPro flags overbought RSI signals and possible overvaluation. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Crinetics Pharmaceuticals Inc en omsætning på 22,01 mio. € og et nettoresultat på -105,89 mio. €

(EUR)	juni 2026	YoY
Omsætning	22,01 mio.	2.416,07 %
Bruttofortjeneste	21,87 mio.	2.400,65 %
Nettoresultat	-105,89 mio.	7,94 %
EBITDA	-115,12 mio.	18,32 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	8,04 mia. €
Antal aktier	106,1 mio.
Højeste/laveste i 52 uger	75,84 € - 28,82 €
Udbytte	Nej
Beta	0,13
P/E (PE Ratio)	-16,82
PEG (PEG Ratio)	0,83
K/I (PB Ratio)	7,52
P/S (PS Ratio)	213,80

Virksomhedsprofil

Crinetics Pharmaceuticals, Inc., et klinisk fase selskab inden for lægemidler, fokuserer på opdagelse, udvikling og kommercialisering af terapier mod sjældne endokrine sygdomme og endokrinrelaterede tumorer. Dets vigtigste produktkandidat er Paltusotine, en oral, selektiv, ikke-peptid somatostatinreceptor type 2-agonist, der har gennemført et fase III-klinisk forsøg til behandling af akromegali, samt gennemført et fase II-klinisk forsøg til behandling af carcinoidsyndrom og ikke-funktionelle neuroendokrine tumorer (NET'er). Selskabet udvikler også CRN04777, en oral, selektiv, ikke-peptid somatostatin type 5-receptoragonist, som er i et fase I-klinisk forsøg til behandling af medfødt hyperinsulinisme; og CRN04894, en oral adrenokortikotrofisk hormonantagonist, der er i et fase I-klinisk forsøg til behandling af Cushings sygdom og medfødt binyrebarkhyperplasi. Crinetics Pharmaceuticals, Inc. blev stiftet i 2008 og har hovedkvarter i San Diego, Californien.

Navn	Crinetics Pharmaceuticals Inc
CEO	R. Scott Struthers
Hjemsted	San Diego, ca USA
Websted	crinetics.com
Sektor	Materialer
Branche	Kemikalier
Børsnotering	18.07.2018
Medarbejdere	594